AbbVie Inc. $ABBV Shares Bought by Aviso Financial Inc.

Aviso Financial Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,764 shares of the company’s stock after purchasing an additional 494 shares during the quarter. Aviso Financial Inc.’s holdings in AbbVie were worth $1,998,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. One Charles Private Wealth Services LLC lifted its position in AbbVie by 11.5% in the second quarter. One Charles Private Wealth Services LLC now owns 5,341 shares of the company’s stock valued at $991,000 after acquiring an additional 550 shares during the last quarter. NDVR Inc. increased its position in shares of AbbVie by 3.5% during the second quarter. NDVR Inc. now owns 2,435 shares of the company’s stock worth $452,000 after purchasing an additional 83 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of AbbVie by 25.7% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 342,136 shares of the company’s stock valued at $63,507,000 after purchasing an additional 70,051 shares during the last quarter. Atalanta Sosnoff Capital LLC boosted its position in shares of AbbVie by 23.4% in the 2nd quarter. Atalanta Sosnoff Capital LLC now owns 511,778 shares of the company’s stock valued at $94,996,000 after purchasing an additional 97,017 shares during the period. Finally, South Plains Financial Inc. grew its stake in AbbVie by 3.6% during the 2nd quarter. South Plains Financial Inc. now owns 5,845 shares of the company’s stock worth $1,085,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research reports. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research report on Tuesday, November 4th. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Wells Fargo & Company increased their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Finally, Morgan Stanley boosted their price target on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Trading Down 2.8%

Shares of ABBV stock opened at $229.61 on Tuesday. The stock has a market cap of $405.81 billion, a P/E ratio of 109.34, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The business has a fifty day simple moving average of $227.05 and a 200-day simple moving average of $205.78.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.